Combined chemotherapy with sequential allogeneic hematopoietic stem cell transplantation successfully treats primary plasma cell leukemia: a case report - Takeaways - MDSpire

Combined chemotherapy with sequential allogeneic hematopoietic stem cell transplantation successfully treats primary plasma cell leukemia: a case report

  • By

  • Xiushuai Dong

  • Jinghua Wang

  • Yaoyao Tian

  • Lianjie Wang

  • Wei Wang

  • May 22, 2026

  • 0 min

Share

  • 1

    Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm with a median overall survival of less than 1 year.

  • 2

    The International Myeloma Working Group updated the diagnostic criteria for pPCL, lowering the threshold for circulating plasma cells to ≥5%.

  • 3

    A 47-year-old female patient achieved long-term disease-free survival after combination chemotherapy followed by allogeneic stem cell transplantation.

  • 4

    The patient initially refused treatment but later consented to a DCEP+T chemotherapy regimen, achieving complete remission.

  • 5

    One month post-transplant, the patient showed complete donor chimerism and only 0.003% normal plasma cells in the bone marrow.

Original Source(s)

Combined chemotherapy with sequential allogeneic hematopoietic stem cell transplantation successfully treats primary plasma cell leukemia: a case report

  • by Xiushuai Dong, Jinghua Wang, Yaoyao Tian, Lianjie Wang, Wei Wang

  • May 22, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer